Omvoh Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The omvoh market research report is one of a series of new reports that provides omvoh market statistics, including the omvoh industry global market size, regional shares, competitors with the omvoh market share, detailed omvoh market segments, market trends, and opportunities, and any further data you may need to thrive in the omvoh industry. This omvoh market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The growth in the forecast period can be attributed to increasing investments in research and development activities, rising disposable income, growing drug approvals, growing cancer disorders, and growing awareness of autoimmune disorders. Major trends in the forecast period include drug approval by authorities, technological advancement in combination therapy, growing demand for personalized medicine, growing research and development activities, and facility expansion.

The growing prevalence of autoimmune diseases is expected to fuel the growth of the Omvoh market. Autoimmune diseases occur when the immune system mistakenly attacks healthy cells, tissues, or organs in the body. The increasing rates of these conditions are influenced by factors such as genetic predisposition, lifestyle choices, hormonal changes, and an aging population. Omvoh works by restoring immune balance, neutralizing harmful antibodies, offering passive immunity, alleviating symptoms, reducing inflammation, and preventing further tissue damage in individuals with autoimmune diseases. For example, in July 2024, the National Health Service (NHS) in England reported that multiple sclerosis affects more than 150,000 people in the UK, with the highest prevalence among women. Each week, about 135 new diagnoses are made, highlighting the growing impact of autoimmune conditions on the population. This rising incidence of autoimmune diseases will drive demand for Omvoh.

The growth of the Omvoh market will also be significantly influenced by increasing healthcare expenditure. Healthcare spending encompasses the total amount allocated to medical care, treatments, and healthcare infrastructure within an economy. The rise in healthcare expenditure is primarily driven by aging populations, the growing prevalence of chronic diseases, advances in medical technology, and greater patient expectations for higher-quality care. As healthcare spending increases, more resources will be directed toward managing autoimmune diseases, improving access to treatments such as Omvoh, which regulate immune responses and improve patient outcomes. For example, in May 2024, a report from the UK’s Office for National Statistics revealed that healthcare expenditure grew by 5.6% in 2023 compared to 0.9% in 2022. This increase in healthcare investment is expected to support the growth of the Omvoh market.

A key trend in the Omvoh market is the development of advanced interleukin-23p19 (IL-23p19) antagonists aimed at improving the treatment of autoimmune diseases and enhancing patient outcomes. IL-23p19 antagonists work by targeting and blocking the p19 subunit of the IL-23 cytokine, which plays a role in inflammation. By inhibiting IL-23, these agents help regulate the immune response, reduce inflammation, and slow the progression of autoimmune diseases. For instance, in December 2024, Eli Lilly and Company announced that Omvoh received a positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for approval in the European Union. This recommendation was supported by data from the Phase 3 VIVID-1 trial, which showed significant improvements in both clinical and endoscopic outcomes compared to a placebo and an active control in patients with moderately to severely active Crohn's disease.

The key company operating in the omvoh market is Eli Lilly and Company.

North America was the largest region in the omvoh market in 2024. The regions covered in omvoh report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the omvoh market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Omvoh is a prescription medication that contains the active ingredient mirikizumab-mrkz, a monoclonal antibody targeting the p19 subunit of interleukin-23 (IL-23), a protein involved in inflammatory responses. It is primarily indicated for the treatment of adults with moderately to severely active ulcerative colitis. The treatment typically starts with intravenous (IV) infusions during the induction phase, followed by subcutaneous injections for ongoing maintenance.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Omvoh is available in both tablet or capsule forms, providing a convenient oral treatment option for chronic inflammatory conditions, ensuring consistent dosing and ease of administration. The medication is used for various clinical indications, including ulcerative colitis (UC), Crohn's disease, psoriasis, and others. It is employed by a range of end users, including hospitals, clinics, pharmacies, and research institutions.

The omvoh market consists of sales of subcutaneous injections, intravenous infusion bags, and lyophilized powder. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.